Waverley Pharma IncTSXV:WAVE
- LAST PRICE0.0100
- TODAY'S CHANGE (%)-0.0050 (-33.3333%)
- Bid / Lots0.0100/ 316
- Ask / Lots0.0200/ 210
- Open / Previous Close0.0150 / 0.0150
- Day Range
- 52 Week Range
- Volume40,000
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | WAVE |
|---|---|---|
| 11:16 ET | 5000 | 0.01 |
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Waverley Pharma Inc | 810.0K | -0.2x | --- |
HAVN Life Sciences Inc | 860.4K | 0.0x | --- |
Entheon Biomedical Corp | 1.2M | -3.0x | --- |
Optimind Pharma Corp | 549.6K | -0.5x | --- |
Chitogenx Inc | 832.3K | -0.2x | --- |
Lophos Holdings Inc | 859.6K | -0.7x | --- |
Company Information
Waverley Pharma Inc. is a biopharmaceutical company engaged in the research, development, and commercialization of human therapeutics focused on oncology. The Company is focused on the generic oncology injectable market in Europe, the United Kingdom (UK), and North America. The Company, through its subsidiaries, has entered into a license, manufacture, supply, marketing and distribution agreement with Reliance Life Sciences Private Limited, which has granted the Company an exclusive territorial license to market and sell capecitabine in the UK and Germany as well as a non-exclusive territorial license to market and sell temozolomide and erlotinib in the UK. Its generic oncology products include bortezomib and pemetrexed. Bortezomib is an injectable generic chemotherapy drug, developed for the treatment of multiple myeloma and mantle cell lymphoma. Pemetrexed is an injectable generic chemotherapy drug, developed for the treatment of non-small cell lung cancer and pleural mesothelioma.
Contact Information
- Headquarters
- 4-1250 Waverley StreetWINNIPEG, MB, Canada R3T 6C6
- Phone
- 204-928-7907
- Fax
- 204-453-1370
Executives
- Chairman of the Board
- Albert Friesen
- President, Chief Executive Officer, Director
- Larry Thiessen
- Chief Financial Officer
- Haaris Uddin
- Independent Director
- P. Marcus Enns
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $810.0K |
|---|---|
Revenue (TTM) | $144.8K |
Shares Outstanding | 54.0M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.51 |
EPS | $-0.04 |
Book Value | $-0.02 |
P/E Ratio | -0.2x |
Price/Sales (TTM) | 5.6 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -1,522.01% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
